Affimed N.V. (AFMD) and UroGen Pharma Ltd. (NASDAQ:URGN) Contrasting side by side

Affimed N.V. (NASDAQ:AFMD) and UroGen Pharma Ltd. (NASDAQ:URGN) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed N.V. 3 0.00 50.52M -0.17 0.00
UroGen Pharma Ltd. 35 1654.47 N/A -5.02 0.00

In table 1 we can see Affimed N.V. and UroGen Pharma Ltd.’s top-line revenue, earnings per share and valuation.


Table 2 provides the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Affimed N.V. 1,677,680,735.89% -22.7% -11.2%
UroGen Pharma Ltd. 0.00% -61.2% -56.8%

Analyst Ratings

The Recommendations and Ratings for Affimed N.V. and UroGen Pharma Ltd. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Affimed N.V. 0 0 0 0.00
UroGen Pharma Ltd. 0 2 0 2.00

UroGen Pharma Ltd. on the other hand boasts of a $45.5 consensus target price and a 90.94% potential upside.

Institutional and Insider Ownership

Institutional investors held 41.7% of Affimed N.V. shares and 75.4% of UroGen Pharma Ltd. shares. Insiders held roughly 8.15% of Affimed N.V.’s shares. On the other hand, insiders held about 1.1% of UroGen Pharma Ltd.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Affimed N.V. 2.74% 1.01% -11.76% -10.18% 71.43% -3.54%
UroGen Pharma Ltd. 6.5% -6.42% -9.76% -17.87% -24.15% -20.81%

For the past year Affimed N.V.’s stock price has smaller decline than UroGen Pharma Ltd.


On 6 of the 10 factors Affimed N.V. beats UroGen Pharma Ltd.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in RaÂ’anana, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.